Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026)

Acadia Pharmaceuticals' Raw Materials history runs 11 years deep, the most recent figure standing at $74.3 million for Q1 2026.

• In Q1 2026, Raw Materials fell 2.84% year-over-year to $74.3 million; the TTM figure through Mar 2026 stood at $74.3 million (down 2.84% YoY), while the FY2025 annual figure was $82.8 million, up 18.7% from the prior year.
• Raw Materials was $74.3 million for Q1 2026 at Acadia Pharmaceuticals, down from $82.8 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $83.7 million in Q2 2025 to a low of $5.2 million in Q1 2023.
• Historically, Raw Materials has averaged $41.6 million across 5 years, with a median of $42.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Raw Materials slipped 16.62% in 2023, then soared 934.36% in 2024.
• A 5-year view of Raw Materials shows it stood at $5.2 million in 2022, then jumped by 501.34% to $31.3 million in 2023, then surged by 122.73% to $69.7 million in 2024, then rose by 18.7% to $82.8 million in 2025, then decreased by 10.21% to $74.3 million in 2026.
• The last three Raw Materials figures came in at $74.3 million (Q1 2026), $82.8 million (Q4 2025), and $77.8 million (Q3 2025), per Business Quant data.